GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Discussion] dose-response looked steeper than anything else in the class and that cuts both ways — 23 comments in the full submission. View in context.
163
c/retatrutide·submitted 9 days ago by u/devils_advocate_d

[Discussion] dose-response looked steeper than anything else in the class and that cuts both ways

Discussionbranch of 7 comments

I have had 11 orders now and I keep a table, so here is the honest summary rather than a vibe. Material has been consistent. Communication has not. Shipping has varied by about 18 days on nominally the same lane, which matters more in summer than in February. The independent number came back 96.8% against a claimed…

Read the full submission and all 23 comments →

This branch

7 comments, started 8 days ago
u/iman_castellanos17 points·8 days ago

What was the dosing schedule in that arm?

replysharereportpermalink
u/discount_math_dm8 points·7 days ago

the 2.5mg arm is different from 2.4mg, results do not transfer

replysharereportpermalink
u/isabela_nilsen2 points·7 days ago

the weight curves are unusually steep, which makes predicting individual response harder

replysharereportpermalink
u/viktor_laurent1 point·7 days ago

Strongly agree. Heart rate escalation needs the actual data, not impressions.

replysharereportpermalink
u/signe_villalobos3 points·7 days ago

TRIUMPH data is phase 2, not phase 3, smaller n and shorter

replysharereportpermalink
u/divya_bakken1 point·7 days ago

TRIUMPH data is phase 2, not phase 3, smaller n and shorter

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

replysharereportpermalink
u/bastian_ekstrom1 point·6 days ago

phase 2 numbers are not maintenance numbers, cite the trial

replysharereportpermalink

← back to the whole thread

About c/retatrutide

Retatrutide: GIP/GLP-1/glucagon triple agonism, the TRIUMPH programme, and the fact that most people discussing it are handling research-grade material with no human-use approval anywhere. Dose-response, heart-rate signal, and the unusually steep phase-2 weight curves get argued about here weekly.

65kmembers
130submissions
Sep 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/retatrutide
c/retatrutide rules
  1. Retatrutide is not approved anywhere for human use. Posts must not read as usage instructions.
  2. Phase 2 numbers are not maintenance numbers. Cite the trial and the dose arm.
  3. Heart-rate and dose-escalation reports need actual measurements, not impressions.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/reta_and_regretu/trialwatch_theou/incretin_ivyu/ledger_mod
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →